DNA Repair Drugs Market Size, Share, Outlook, and Opportunity Analysis, 2020– 2027

DNA REPAIR DRUGS MARKET ANALYSIS INDUSTRY INSIGHTS, TRENDS, OUTLOOK, AND OPPORTUNITY ANALYSIS, 2020–2027

REPORT DESCRIPTION DNA Repair Drugs Market - Overview Global DNA Repair Drugs Market, by Drug Type (Niraparib (Zejula), Olaparib (Lynparza), Rucaparib (Rubraca), and Talazoparib (Talzenna)), by Application (Ovarian Cancer, and Breast Cancer), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) was valued US$ 461.3 million in 2017, and projected to exhibit CAGR of 32.4% over the forecast period (2018 – 2026), as highlighted in a new report published by . Increasing collaborations and acquisitions. Key players in the market are focusing on strategic collaborations and acquisitions, to increase their geographical positioning and expand their product portfolio in the global DNA repair drugs market. In July 2017, AstraZeneca and Merck & Co., Inc. announced plans to collaborate over the development and commercializing of AstraZeneca’s LYNPARZA (olaparib) indicated in treatment of multiple cancer types. In January 2018, AstraZeneca Plc. received an approval from the Japanese Ministry of Health, Labor and Welfare for Lynparza (olaparib) tablets used as maintenance therapy for patients with platinum-sensitive relapsed ovarian cancer. Moreover, rising investment and funding by regional governments and other organizations is expected to boost the market growth. In February 2019, the Liberal National Government of Australia announced an investment of US$ 1.14 Mn for an innovative pilot project supporting women with ovarian cancer. Browse Research Reports: https://www.coherentmarketinsights.com/market-insight/dnarepair-drugs-market-2617 © Coherent market Insights. All Rights Reserved

REPORT DESCRIPTION Browse 31 Market Data Tables and 24 Figures spread through 206 Pages and in-depth TOC on ‘DNA Repair Drugs Market’- Global Forecast to 2026, by Drug Type (Niraparib (Zejula), Olaparib (Lynparza), Rucaparib (Rubraca), and Talazoparib (Talzenna)), by Application (Ovarian Cancer, and Breast Cancer), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) Furthermore, increasing incidence of cancer, is expected to drive the market growth. According to the World Cancer Research Fund International’s report in 2018, breast cancer accounted for second highest number of cancer cases among all the cancer cases worldwide, accounting 2,088,849 new cases across the globe in 2018. Key players are focused on partnerships and acquisitions in order to expand their product portfolio in the global DNA repair drugs market. In May 2019, Clovis Oncology, Inc., in collaboration with Bristol-Myers Squibb Company and Foundation Medicine Inc., initiated Phase II trials to evaluate efficacy of Rucaparib in combination with Nivolumab in patients with high-grade serous carcinoma (HGSC) or endometrioid ovarian cancer. In January 2019, GlaxoSmithKline plc. a U.K.-based company, acquired TESARO, Inc. for around US$ 5.1 billion for drug development of Zejula in multiple cancer treatments.

The government included Lynparza in its 'Pharmaceutical Benefits Scheme' which can save medicine expenses of patients up to US$ 64,400 a year. Request a Sample copy of this reports: https://www.coherentmarketinsights.com/insight/request-sample/2617 © Coherent market Insights. All Rights Reserved

REPORT DESCRIPTION Key Takeaways of the DNA Repair Drugs Market: The global DNA repair drugs market is expected to exhibit CAGR of 32.4% over the forecast period, due to increasing incidence of cancer. According to the World Health Organization (WHO), 2012, cancer is the second leading cause of morbidity and mortality worldwide, with 14 million new cases registered in 2012. Furthermore, the WHO stated that the number of new cases is expected to rise by 70% in 2030. Among drug types, the Olaparib (Lynparza) segment dominated the global DNA repair drugs market in 2018, owing to increasing number of product approvals in developed and emerging economies around the globe. For instance, in May 2019, AstraZeneca plc. and Merck received the Health Canada approval for Lynparza as a monotherapy maintenance treatment for patients with advanced BRCA-mutated high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer. Among application, the ovarian cancer segment held dominant position in the global DNA repair drugs market in 2018, as DNA repair drugs are largely used for treatment of ovarian cancer. Key players operating in the global DNA repair drugs market are AstraZeneca Plc., Johnson & Johnson, GlaxoSmithKline plc., Pfizer, Inc., Clovis Oncology Inc., AbbVie Inc., Bristol - Myers Squibb, Merck KGaA, Genentech, Inc., Repare Therapeutics Inc., Karyopharm Therapeutics Inc., Ono Pharmaceutical Co., LTD., and Jiangsu Hengrui Medicine Co., Ltd.

ABOUT COHERENT MARKET INSIGHTS ABOUT US Coherent Market Insights is a global market intelligence and consulting organization focused on assisting its plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, with an office at the global financial capital in the U.S. Our client base includes players from across all business verticals in over 150 countries worldwide. We are uniquely positioned to help businesses around the globe deliver practical and lasting results through various recommendations about operational improvements, technologies, emerging market trends and new working methods. We offer both customized and syndicated market research reports that help our clients create visionary growth plans to provide traction to their business. We meticulously study emerging trends across various industries at both the global and regional levels to identify new opportunities for our clientele.

SERVICES INDUSTRY ANALYSIS

CUSTOMIZED RESEARCH

SYNDICATED RESEARCH

MARKET INTELLIGENCE SERVICES

CONSULT STUDIES

COUNTRY SPECIFIC STUDIES

ABOUT CMI SECTOR COVERAGE

BIOTECHNOLOGY

CLINICAL DIAGNOSTIC

HEALTHCARE IT

MEDICAL DEVICES

MEDICAL IMAGING

PHARMACEUTICAL

OUR CLIENTS

 Global Leading Equipment and System Manufacturers  Marketing Consultancies and the Advertising Industry  Component Providers and System Integrators

 Private and Government organization

 Distributors, Retailors and Value Added Resellers

 Outsourcing Companies

 Healthcare IT Solutions Developers

 Universities and Business Schools.

KEY STATS

RESEARCH SOLUTIONS

100+

FEASIBILITY STUDIES

Insights Published Per Year

GLOBAL REPORTS

150+

Consulting Projects Till Date

COUNTRY ANALYSIS CONSULT PROJECTS

125+

Clients Worldwide Per Year

110+

SURVEY RESEARCH

EXCEL FORECAST DATABASE

CUSTOMIZED SOLUTIONS

COMPETITIVE ASSESSMENT TECHNOLOGY SNIPPETS

Analysts and Contract Consultants

Coherent Market Insights excels at offering unmatched actionable market intelligence across various industry verticals, including chemicals, healthcare, and food & beverages, to name a few. We implement holistic market research methodology in order to result in the best possible market research reports across various industries worldwide. Based on our unmatched expertise across various industries—no matter how large or small, how complex or unique—we help our clients achieve better outcomes with uniquely designed and highly customized solutions. Our coverage includes insights that help our clients ensure sustained growth in developed markets and also key inputs to help them tap into emerging markets and exploit the plethora of opportunities posed therein. © Coherent market Insights. All Rights Reserved

THANK YOU To know more about us, visit our website: www.coherentmarketinsights.com For sales queries or new topics email us on: sales@coherentmarketinsights.com For other queries contact: Mr. Shah (Manager - Business Development) Coherent Market Insights sales@coherentmarketinsights.com +1-206-701-6702

Turn static files into dynamic content formats.

Create a flipbook